Pillary vs poorly differentiated), age, and sorafenib remedy, but not BRAF
Pillary vs poorly differentiated), age, and sorafenib remedy, but not BRAF or RAS mutation status, were independently prognostic for PFS benefit (Appendix D, Table D3). Similarly, mutation status was not…